Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
Risk & Volatility
Palvella Therapeutics has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Palvella Therapeutics and Silo Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palvella Therapeutics | 1 | 0 | 13 | 2 | 3.00 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
Insider and Institutional Ownership
40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by insiders. Comparatively, 2.2% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Palvella Therapeutics and Silo Pharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palvella Therapeutics | $42.81 million | 33.41 | -$17.43 million | ($2.63) | -45.93 |
| Silo Pharma | $70,000.00 | 61.84 | -$4.39 million | ($0.95) | -0.34 |
Silo Pharma has lower revenue, but higher earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Palvella Therapeutics and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palvella Therapeutics | N/A | -64.41% | -42.74% |
| Silo Pharma | -7,050.00% | -107.03% | -77.06% |
Summary
Palvella Therapeutics beats Silo Pharma on 10 of the 15 factors compared between the two stocks.
About Palvella Therapeutics
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
